Navigation Links
New Study by BioTrends Highlights Practice Management Shifts Among Canadian Nephrologists
Date:11/19/2008

EXTON, Pa., Nov. 19 /PRNewswire/ -- BioTrends Research Group, Inc. released its first TreatmentTrends(TM): Canadian Nephrology Report. This report runs parallel to two ongoing studies BioTrends conducts -- TreatmentTrends(TM): US and European Nephrology. The report is based on the results of an on-line survey completed by 40 Canadian Nephrologists and focuses on the management of renal anemia and hyperphosphatemia.

In the anemia market, Amgen's Aranesp is the market share leader among patients with Chronic Kidney Disease not on dialysis (CKD) whereas share between Aranesp and Eprex in the dialysis market is more evenly divided. Satisfaction between brands is similar, but Eprex has a perceived competitive advantage on achieving target hemoglobin levels quickly and allowing for easy dosing modifications. Aranesp, on the other hand, has a perceived advantage when it comes to extended dosing intervals, an attribute that is considered more important in CKD than in dialysis. No significant shifts in projected use of ESAs or in ESA market share are expected in the next six months. Unaided awareness of new ESAs in development is very low. Of those who are aware, Roche's Mircera is most often mentioned.

Use of IV iron is limited outside of hemodialysis with less than 20% of peritoneal dialysis, less than 15% of Stage 4 CKD and less than 5% of Stage 3 CKD patients receiving therapy. American Regent's Venofer is the market share leader in both dialysis and CKD, but their margin over Watson's Ferrlecit is greater in CKD. Company contact through sales representatives is virtually non-existent for all the IV iron players with almost 100% of Nephrologists reporting no contact in more than three months, and often never. The IV iron market is expected to stay relatively stagnant in the next six months.

In the phosphate binder market, calcium carbonate continues to be the binder used in the vast majority of CKD and dialysis patients, a decision that seems primarily driven by cost / reimbursement. Familiarity with Genzyme's Renagel is high, as are perceptions of its performance on the most important phosphate binder attributes, but use of the product tends to be limited to second line therapy. Current share for Shire's Fosrenol is relatively low but Nephrologists project a significant increase in use to close to 10% market share in the dialysis setting in the next six months, with decreases projected for both calcium-based binders and Renagel. Current use of FMC's PhosLo is also low, but Nephrologists expect increases in use among both dialysis and CKD patients in the next six months. Calcium carbonate, however, is expected to remain the go to calcium-based binder with approximately 90% of the calcium business.

About BioTrends Research Group, Inc.

BioTrends Research Group, Inc. (www.bio-trends.com) provides syndicated and custom market research to pharmaceutical manufacturers competing in clinically evolving, specialty pharmaceutical markets. For information on BioTrends publications and research capabilities, please contact us at (610) 363-3872 or www.bio-trends.com.

All company, brand, or product names contained in this document may be trademarks of their respective holders.


'/>"/>
SOURCE BioTrends Research Group, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related medicine news :

1. Penn study finds pro-death proteins required to regulate healthy immune function
2. New study shows promise in reducing surgical risks associated with surgical bleeding
3. Study, meta-analysis examine factors associated with death from heatstroke
4. Study suggests loss of 2 types of neurons -- not just 1 -- triggers Parkinsons symptoms
5. Study says COPD testing is not measuring up
6. Preclinical study suggests organ-transplant drug may aid in lupus fight
7. Ability to cope with stress can increase good cholesterol in older white men, study finds
8. High alcohol consumption increases stroke risk, Tulane study says
9. Mailman School of Public Health study examines link between racial discrimination and substance use
10. Pitt study finds inequality in tobacco advertising
11. Stanford study highlights cost-effective method of lowering heart disease risks
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/24/2017)... ... April 24, 2017 , ... The world-class ... support to bring their novel lifesaving device for the everyday use of parents ... sensors, specially designed to read a child’s vital signs, and detect unusual symptoms ...
(Date:4/24/2017)... Ill., and Waycross, Ga. (PRWEB) , ... April ... ... market leader and trusted advisor within the telehealth industry, announces the company’s VideoMedicine ... U.S. board-certified primary care providers. Available 24 hours a day, Quick Care provides ...
(Date:4/24/2017)... ... April 24, 2017 , ... According ... overdose deaths now claim the lives of 62 Americans each day.(1) Yet since ... drug manufacturers, distributors, pharmacies and prescribers by more than half.(2) Novus Medical ...
(Date:4/24/2017)... ... April 24, 2017 , ... ... recognize elevated anxiety levels in people with addiction who are served by MAP’s ... a biosensing wearable device that monitors heart and breath rates to identify anxiety ...
(Date:4/24/2017)... ... 2017 , ... Pitavastatin, a relatively new statin, has relevance ... to have significant interactions with antiretroviral therapy (ART). Among people living with ... inflammation in the bloodstream. , While lowering cholesterol and dampening inflammation are beneficial ...
Breaking Medicine News(10 mins):
(Date:4/20/2017)... April 20, 2017 NeuroVive Pharmaceutical AB ... announced positive preclinical results demonstrating anti-fibrotic effects ... non-alcoholic steatohepatitis (NASH), in an additional well-validated ... NV556 has previously shown similar anti-fibrotic effects ... NeuroVive,s scientists present novel data demonstrating anti-fibrotic ...
(Date:4/19/2017)...  IRIDEX Corporation (Nasdaq: IRIX ) today ... first quarter 2017 after the close of trading on ... host a corresponding conference call beginning at 2:30 p.m. ... in listening to the conference call may do so ... 326-3030 for international callers, using conference ID: 92158987.  A ...
(Date:4/19/2017)... 19, 2017  Sorrento Therapeutics, Inc. (NASDAQ: ... company developing new treatments for cancer and other ... its previously announced underwritten public offering of 23,625,084 ... offering price of $2.00 per share, before deducting ... payable by Sorrento.  The net proceeds to Sorrento ...
Breaking Medicine Technology: